<DOC>
	<DOC>NCT01273779</DOC>
	<brief_summary>Study will evaluate the safety and potential benefit of talactoferrin (recombinant human lactoferrin) as an addition to the standard care for severe sepsis.</brief_summary>
	<brief_title>Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis</brief_title>
	<detailed_description />
	<mesh_term>Sepsis</mesh_term>
	<mesh_term>Toxemia</mesh_term>
	<mesh_term>Lactoferrin</mesh_term>
	<criteria>Age greater than or equal to 18 years Onset of severe sepsis within the previous 24 hours Must be receiving antibiotic therapy Informed consent form signed by patient or authorized representatives according to local rules or regulations Able to take liquid medication by mouth or feeding tube Receipt of investigational medication within 4 weeks prior to participation in the study Pregnant or breastfeeding Severe congestive heart failure Known severe HIV infection Presence of severe burns Patients on high dose immunosuppressants Patients whose death is considered imminent Patients whose life expectancy for concurrent illness is less than 6 months Severe hypoxic encephalopathy or persistent vegetative state Severe liver disease Chronically bed bound Patient, legal representative or patient's primary physician not committed to providing full, aggressive life support</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
	<keyword>sepsis</keyword>
	<keyword>talactoferrin</keyword>
	<keyword>lactoferrin</keyword>
	<keyword>recombinant human lactoferrin</keyword>
</DOC>